Insys Therapeutics Inc (INSY) Receives $8.50 Average PT from Analysts

Share on StockTwits

Insys Therapeutics Inc (NASDAQ:INSY) has been assigned a consensus rating of “Hold” from the eight research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.50.

Several equities research analysts recently commented on INSY shares. Zacks Investment Research raised Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 4th. ValuEngine cut Insys Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 13th. Finally, Janney Montgomery Scott reissued a “buy” rating and issued a $11.00 price target on shares of Insys Therapeutics in a research note on Wednesday, December 19th.

Shares of INSY traded down $0.03 during trading hours on Friday, reaching $4.64. The company’s stock had a trading volume of 5,364 shares, compared to its average volume of 554,012. The company has a market capitalization of $332.73 million, a price-to-earnings ratio of -9.45 and a beta of 2.07. Insys Therapeutics has a 1-year low of $3.35 and a 1-year high of $11.65.

Insys Therapeutics (NASDAQ:INSY) last issued its earnings results on Monday, November 5th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.30 million during the quarter, compared to analyst estimates of $24.05 million. Insys Therapeutics had a negative net margin of 128.88% and a negative return on equity of 266.60%. Insys Therapeutics’s revenue for the quarter was down 40.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.30) EPS. On average, equities analysts predict that Insys Therapeutics will post -1.32 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in shares of Insys Therapeutics in the 3rd quarter valued at approximately $113,000. Creative Planning bought a new stake in Insys Therapeutics during the third quarter worth approximately $153,000. Tower Research Capital LLC TRC bought a new stake in Insys Therapeutics during the second quarter worth approximately $131,000. MetLife Investment Advisors LLC bought a new stake in Insys Therapeutics during the third quarter worth approximately $223,000. Finally, BlueMountain Capital Management LLC boosted its position in Insys Therapeutics by 533.6% during the third quarter. BlueMountain Capital Management LLC now owns 28,145 shares of the specialty pharmaceutical company’s stock worth $284,000 after purchasing an additional 23,703 shares during the period. 17.22% of the stock is owned by institutional investors and hedge funds.

About Insys Therapeutics

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Read More: Intrinsic Value and Stock Selection

Analyst Recommendations for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.